Initial outcomes and insights from a novel high‐risk prostate cancer screening clinic. Issue 2 (7th October 2022)

• Record Type: Journal Article
• Authors: Harper, Jonathan B.; Greenberg, Samantha E.; Hunt, Trevor C.; Cooney, Kathleen A.; O'Neil, Brock B.
• Is Part Of: Prostate. Volume 83:Issue 2(2023)
• Page Start: 151
• Page End: 157
• Publication Date: 2022-10-07
• Subjects: early detection of cancer -- genetic counseling -- patient‐reported outcome measures -- prostate cancer—familial -- prostate cancer—hereditary -- prostatic neoplasms; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.24447
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Introduction: Guidelines for germline testing in patients with prostate cancer (PCa) are identifying family members who require additional surveillance given pathogenic variants (PVs) that confer increased PCa risk. We established an interdisciplinary clinic for cancer surveillance in high‐risk individuals aimed to implement screening recommendations. This study aimed to characterize the clinical features of this cohort. Patients and Methods: The Prostate Cancer Risk Clinic (PCRC) was established for unaffected individuals with germline PVs or a strong PCa family history. PCa screening, urine labs, and questionnaires were included in the visit. Individuals with BRCA1/2 PVs underwent clinical breast exam as well. Data from the initial visit were abstracted from the medical record and questionnaires for analysis. Results: Thirty‐five individuals with increased PCa risk were followed by the PCRC with a median age of 47 years of age. Twenty individuals (57%) had a family history of PCa, and 34 (97%) had a germline PV associated with an increased risk for developing PCa. Four individuals underwent biopsy due to care in the PCRC, with one PCa identified in an individual with TP53 PV. Median patient response scores indicated mild symptoms of an enlarged prostate (AUASS), normal erectile function (SHIM), and relatively low anxiety about developing PCa (MAX‐PC). However, there were notable "outlier" scores on each questionnaire. Conclusions: Individuals with prostates and BRCA1/2 PVs, among other germline PVs, can benefit from a comprehensive interdisciplinary approach to high‐risk management. PCa was identified in an individual with a non‐ BRCA PV, emphasizing the importance and need for high‐risk screening guidelines across all genes with increased risk for PCa. "Outlier" patient response scores demonstrate that some participants experienced worse symptoms or anxiety than was indicated by median scores alone.